TORONTO and HOUSTON, May 1, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today that it has received US$757,940 (approximately, CD$1.02M) from the Cancer Prevention and...
from PR Newswire: https://prn.to/2IV2oqz
No comments:
Post a Comment